Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 6/20 | 0.47 |
| ▸ | ICMT | O60725 | 2/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.43 |
| ▸ | HTR1D | P28221 | 3/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | HTR1B | P28222 | 2/20 | 0.43 |
| ▸ | MC5R | P33032 | 3/20 | 0.42 |
| ▸ | MC3R | P41968 | 3/20 | 0.42 |
| ▸ | MC4R | P32245 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL7589346 | 0.85 | LTA4H (0.40) | MPOHTR7LTA4HPLA2G2AHTR1D | |
| SCHEMBL7325860 | 0.83 | LTA4H (0.59) | MPOHTR7LTA4HPLA2G2AHTR1D | |
| Hydrochloric Acid SCHEMBL7312565 | 0.81 | LTA4H (0.61) | MPOHTR7LTA4HPLA2G2AHTR1D | |
| Tryptamine SCHEMBL4776238 | 0.74 | HTR7 (0.71) | MPOHTR7HTR1DHTR1AHTR1B | |
| SCHEMBL7324142 | 0.73 | HTR1A (0.60) | MPOHTR7HTR1DHTR1AHTR1B | |
| SCHEMBL27596004 | 0.71 | HTR2A (0.59) | MPOHTR7HTR1DHTR1AHTR1B | |
| SCHEMBL7325786 | 0.71 | CSNK2A1 (0.55) | MPOICMTLTA4HPLA2G2AMC5R | |
| SCHEMBL7391299 | 0.71 | HTR6 (0.51) | MPOICMTHTR7HTR1DHTR1A | |
| Trifluoroacetic Acid SCHEMBL7401358 | 0.70 | MCL1 (0.40) | — | |
| Trifluoroacetic Acid SCHEMBL7318294 | 0.69 | NTSR1 (0.45) | ICMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010007877-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION | 2001-07-12 | — | — | US | claimed |
| WO-2001034146-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-17 | — | — | WO | claimed |
| US-20020004198-A1 | Novel anti-infectives | SMITHKLINE BEECHAM CORPORATION | 2002-01-10 | — | — | US | disclosed |
| US-20010007877-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION | 2001-07-12 | — | — | US | disclosed |
| WO-2001034146-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010007877-A1 | NOVEL ANTI-INFECTIVES | CTSL, MMP8, SERPINB1 | MPO 87/4885ICMT 1459/4885HTR7 4398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.